Remdesivir trial results: NEJM, NIAID and Gilead provide conflicting information
Information shared by the three stakeholders — NEJM, NIAID and Gilead — on critical issues about whether the drug’s ability
Read More
Day: May 24, 2020
Information shared by the three stakeholders — NEJM, NIAID and Gilead — on critical issues about whether the drug’s ability
Read More